A8D Stock Chart & Stats
€0.73
€0.17(32.04%)
At close: 4:00 PM EDT
€0.73
€0.17(32.04%)
Day’s Range― - ―
52-Week Range€0.52 - €1.55
Previous CloseN/A
Volume0.00
Average Volume (3M)26.00
Market Cap
€50.58M
Enterprise Value€55.79M
Total Cash (Recent Filing)€8.98M
Total Debt (Recent Filing)€4.74M
Price to Earnings (P/E)―
Beta0.41
Next Earnings
Apr 23, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.08
Shares Outstanding96,530,785
10 Day Avg. Volume80
30 Day Avg. Volume26
Financial Highlights & Ratios
PEG Ratio0.73
Price to Book (P/B)-5.48
Price to Sales (P/S)80.33
P/FCF Ratio-20.63
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.15
Revenue Forecast (FY)€1.20M
Bulls Say, Bears Say
Bulls Say
Revenue GrowthImproving revenue growth indicates that AB Science is generating increasing commercial or development-related inflows despite its small scale. If this trend continues, a larger revenue base could gradually improve operating leverage and provide greater support for advancing its pipeline.
Debt ReductionThe substantial reduction in debt lowers fixed financial obligations and reduces exposure to interest or refinancing pressure. Although the balance sheet remains fragile, this deleveraging gives the company more flexibility than it would have had with the materially higher debt burden of prior years.
Proprietary Drug PipelineOwnership of a proprietary clinical-stage asset gives AB Science potential to create value through approvals, commercialization, licensing, milestones, or royalties. Masitinib’s investigation across multiple disease areas provides several development pathways rather than relying on a single narrowly defined indication.
Bears Say
Persistent UnprofitabilityContinued operating and net losses show that the business has not yet reached an economically sustainable scale. Persistent unprofitability can consume capital needed for clinical development and makes future earnings dependent on successful approvals, commercialization, or additional funding.
Negative Shareholder EquityNegative equity is a major structural weakness because liabilities exceed recorded assets and financial flexibility is constrained. This fragile capital structure leaves AB Science more sensitive to further operating losses and increases the importance of securing sufficient funding for ongoing development.
Renewed Cash BurnThe return to substantial operating and free-cash-flow burn demonstrates that internal cash generation is not dependable. If this pattern persists, AB Science may need to raise capital or secure partner funding, potentially limiting strategic flexibility while its pipeline remains in development.
AB Science SA News
A8D FAQ
What was AB Science SA’s price range in the past 12 months?
AB Science SA lowest stock price was €0.52 and its highest was €1.55 in the past 12 months.
What is AB Science SA’s market cap?
AB Science SA’s market cap is €50.58M.
When is AB Science SA’s upcoming earnings report date?
AB Science SA’s upcoming earnings report date is Apr 23, 2027 which is in 193 days.
How were AB Science SA’s earnings last quarter?
AB Science SA released its earnings results on Oct 09, 2026. The company reported -€0.13 earnings per share for the quarter, missing the consensus estimate of -€0.07 by -€0.06.
Is AB Science SA overvalued?
According to Wall Street analysts AB Science SA’s price is currently Overvalued.
Does AB Science SA pay dividends?
AB Science SA does not currently pay dividends.
What is AB Science SA’s EPS estimate?
AB Science SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does AB Science SA have?
AB Science SA has 96,530,785 shares outstanding.
What happened to AB Science SA’s price movement after its last earnings report?
AB Science SA reported an EPS of -€0.13 in its last earnings report, missing expectations of -€0.07. Following the earnings report the stock price went down -0.771%.
Which hedge fund is a major shareholder of AB Science SA?
Currently, no hedge funds are holding shares in DE:A8D
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
AB Science SA
AB Science S.A. is a pharmaceutical company dedicated to the discovery, development, and commercialization of protein kinase inhibitors for applications in both human and animal health. Its primary drug candidate, masitinib, a tyrosine kinase inhibitor, is currently undergoing late-stage (Phase III) clinical investigations for a range of serious conditions including prostate cancer, pancreatic cancer, amyotrophic lateral sclerosis (ALS), multiple sclerosis, Alzheimer's disease, severe asthma, and mastocytosis. Additionally, masitinib is being evaluated in Phase II clinical trials for the treatment of Covid-19. The company's pipeline also features AB8939, a synthetic microtubule destabilizer aimed at treating acute myeloid leukemia, and AB20001, which is in Phase 2 trials to assess the safety and efficacy of masitinib combined with isoquercetin in hospitalized patients experiencing moderate to severe COVID-19. Masitinib is sold under the brand name Masivet in the European market. AB Science S.A. was founded in 2001 and is based in Paris, France.